Index

Page numbers in italic refer to figures.
The numbers in bold refer to tables.
Sorting is in letter-by-letter order so that, for example, “B cells” comes before “BI201335”.
Terms starting with numerals are sorted according to pronunciation of initial numeral so that “5BSL3.2” comes after “fitness cost”.

A181V mutation, drug resistance, 198
A194T mutation, drug resistance, 198
A1896 substitution, see G1896A substitution
abacavir, drug interactions, 491, 501
ABT-072 (NS5B inhibitor), 385, 386
ABT-333 (NS5B inhibitor), 385, 386
ACCELERATE trial, 364
accident and emergency departments, HCV, 522–523
acetaminophen, acute liver failure, 469
renal failure, 480
2-acetylaminofluorene (2-AAF), progenitor cell response model, 7
N-acetylaspartate (NAA), central nervous system, HCV infection, 314
acetylation, HDAG, 397
N-acetyl cysteine, 479
aciclovir
Epstein–Barr virus, 536
neonatal HSV, 532
acid suppression therapy, 480
acoustic radiation force impulse imaging (ARFI), 347
activated factor VII, 480
activator protein 1, liver regeneration, 6
acupuncture, HCV and, 251
acute hepatitis
children, 533–542
HBV infection, 456, 472–474
 carriers, 144
extrabiliary manifestations, 155
flares, 144–145, 150
HBV transgenic mouse models, 177–179
healthcare workers, 515–516
HIV infection, 495
hydrodynamically transfected HBV mouse models, 179–180
immune complexes, 155, 156
precore variants, 133
prognosis, 155
HCV infection, 461, 462, 475–476
after liver transplantation, 204
HIV infection, 500–501
immune response, 267
HEV infection, 443–444, 446
ribavirin, 446
investigations, 471
treatment, 468–485
acute nonfulminant hepatitis, HBV, precore variants, 133
acute-on-chronic liver failure, 474
acute-on-chronic viral hepatitis, HBV infection, 474
acylated pre-S peptides, HDV infection, 414
adaptive immunity, 20–21
murine models, HBV, 178–179, 183–184
adefovir (ADV)
HBV infection, 473
children, 540
HBsAg-positive chronic, 194
lamivudine with, 197
nephrotoxicity, 196
renal impairment, 211–212
rescue therapy for drug resistance, 199
HDV infection, 413, 414
adenosine acting on RNA-1 (ADAR-1), 396–397
adenoviruses, see also DNA prime adenovirus boost immunization
acute liver failure, 469, 477
children, 530
neonates, 533
a determinant mutations, HBV, 110–111
antigenicity, 114–115
assay results, 118
carriers, 116–117
first loop, 114
passive immunization and, 112–114
residues 100–124, 114
second loop, 114–115
adjuvants
HAV vaccines, 50, 51, 54
HBV vaccines, 518
hepatocellular carcinoma, 548
adolescents, HCV infection, treatment, 373
adoptive transfer, HBV transgenic mouse models
CD8+ T cells, 178
splenocytes, 177–178, 179
ADVANCE study, HCV infection, 365, 382
adverse events
hepatitis A vaccines, 53, 58
hepatitis B vaccine, 92
interferon, 195, 370
recurrent hepatitis C, 205
nucleos(t)ide analogs, 196
protease inhibitors, 368
ribavirin, 370
 aflatoxin B1, p53 mutation, 171
Africa
HCV, 261–262
Sub-Saharan, migrants from, 509
age
HBeAg seroconversion, 146
HBsAg, spontaneous seroclearance, 147
hepatitis A vaccine response, 53
HAV infection, 35, 47, 48
HCV infection
 liver fibrosis progression, 343
treatment response, 371
HEV infection, 477
aging
liver donors, 204
on liver regeneration, 5–6
Ago2, HCV binding and, 234
Index

Index

HDV, 399
HEV, 427
astrocytes, HCV, 518
asunaprevir, 374–375, 378, 384
asymptomatic carriers, see carriers
atherosclerosis, HCV infection and, 307
attachment, HBV, 73–74
attenuated vaccines, HAV infection, 58
AUG start codons, HBV, 77
autopsy studies, HCV, central nervous system, 317–318
auxiliary liver transplantation, 482
Avaxim (hepatitis A vaccine), 51
avian HEV, 438
aviation hepatitis, 470
autophagosomes, HCV infection, 231
autophagy
HCV NS4B and, 233
induction by HCV, 272–273
autopsy studies, HCV, central nervous system, 317–318
bacteria, sterilization, 569
baltimore, HDV prevalence, 405
barbers, see hairdressers
Barcelona Clinic Liver Cancer staging, 546–547
barriers to migrants
perceived, 511
real, 511–513
basal core promoter (BCP), HBV, 75, 76, 129
hepatocellular carcinoma, 150, 164
variants, 133–134, 135, 139
baseline anticipation score, HDV infection, 407
B Asia (genotype division), HBV, 88
bat hepevirus, 438
B cell(s), 21
HBV infection, chronic hepatitis, 184
HCV infection, 266, 296–297
treatments, 301–302
in vitro, 337
as virus selection pressure, 377
B cell epitopes, HBV, 108
mutations evolving, 114
B cell non-Hodgkin lymphoma
HBV infection, 160
HCV infection, 298, 357, 463
treatment, 302
bec-2 gene, mixed cryoglobulinemia, 297
behavioral models, viral hepatitis, migrants, 510–511
benefits, perceived, 511
β-catenin gene, hepatocellular carcinoma, 172, 357
BI201335 (protease inhibitor), 383–384
BIL201712 (NS5B inhibitor), 386
big liver and spleen disease (BLS disease), chickens, 345, 346, 348
biopsy, see liver biopsy
birth dose, hepatitis B vaccine, 93–94
bites, HBV transmission, 516
bivalve mollusks, HAV infection, 46
B Japan (genotype division), HBV, 88
blood
decomantion, 572, 573
HBV transmission, 516, 518, 519, 520–521
bloodborne transmission, see also blood transfusion; injection drug use;
inoculation injuries; needlestick injury
HAV, 44, 46–47
on virus evolution, 581
blood-brain barrier, HCV infection, 319
blood transfusion
HAV, 47
HBV, 83–84
evolved variants, 117
HCV, 247, 248–249
boars, wild, HEV, 433
boceprevir, 382, 383, 384
drug interactions, 491
drug resistance, 369
HCV infection, 363, 364–365, 366, 378
HIV co-infection, 372, 503
mixed cryoglobulinemia, 302
monitoring, 561
recurrent, 208
molecule, 383
toxicity, 368–369
body fluids, HBV transmission, 516
boosting of vaccination
DNA prime adenoavirus boost immunization, 102–103
DNA prime–viral vector boost (Ad5/35) immunizations, woodchuck, 104
HBV, 517
modified vaccinia Ankara boost vaccination, 104
natural boosting (maternal), 93
protease inhibitors, 384
bovine HEV, 436
bovine viral diarrhea virus, ortho-phthalaldehde, 572
brain microvascular endothelial cell lines, HCV, 438
branched DNA technology, 553
Brazil, HDV prevalence, 405
breakthrough infections in antiviral treatment, 198–199
HAV, 92–93
HAV infection, 36
breast cancer, HCV infection and, 307
breast milk
HCV and, 252
nucleos(t)ide analogs, 457
Butcher–Chiaristi syndrome, 470
budgerigars, endogenous Hepadnaviridae, 99
butchers, HBV, 516, 521
Butte County (California), hepatitis A vaccination, 56
“bystander” damage, viral infections, 22
calcineurin inhibitors
liver transplantation, 205
protease inhibitors and, 208, 369
calnexin, 227
Canadian Aborigines, HCV, 259
canal of Hering, 7
cancer stem cells, 9
capped genomic HEV RNA, 422
capsid(s), see also encapsidation, HAV, 32
capsid proteins, HEV E2s domain, 427–428
ORF2 protein, 423–424, 437
p239, 426
carboxypeptidase B, 73
care facilities, see also daycare centers
childcare centers, HAV vaccination, 58
HAV infection, 83, 86–87
Caroli’s triad, 159
carriers
HBV, 131–132, 144, 455, 539, see also inactive phase; occult HBV infection
anti-HBe-negative, 149
B cell non-Hodgkin lymphoma, 160
diagnosis, 557
DNA serum levels, 147
escape mutations, 116–117
healthcare workers, 515, 519–521
hepatocellular carcinoma, 164
monitoring, 191
from perinatal transmission, 534
prevalence, 516
variants, 139
HCV, 281
migrants, 508, 509
caspase-1, 20
casualty departments, HCV, 522–523
catch-up vaccination, HBV infection, 94
cattle, HEV, 436
CBF/p300 (CREB-binding protein), 72
cirrhosis
HBV infection, 85, 149
genotypes, 89
hepatocellular carcinoma, 164
HIV co-infection, 497
nucleos(t)ide analogs, 190
reactivation, 149
HCV infection, 341
decompensated, 208
prevalence, 343
transient elastography, 346–347, 348
treatment during, 372
on treatment response, 366
treatment to prevent, 370
HDV, 407
hepatocellular carcinoma, 353–354
treatment, 547–549
median expected time to, 342–343
proton magnetic resonance spectroscopy of CNS, 314
cis-acting elements
HBV core promoter, 129, 133
HCV genome, 235
HEV, 422
Phi, HBV DNA synthesis, 77
cis-acting promoter, HBV and hepatocellular carcinoma, 170
clams, HAV infection, 46
classically activated macrophages (M1 macrophages), 15
claudin-1 (CDLN-1), HCV, 227
estrahepatic cells, 318
cleaning, laboratories, 572–573
clearance (spontaneous), HBsAg, 147–148
clemizole, 386
clevudine, vaccination and, woodchuck model, 102
clotting factor concentrates, 486–487, 492
clustered mutations, HCV, CD8+ T cell escape, 275
clusterin, HDV infection, 400
cogulopathy, 480
Cobas Ampliprep®/Cobas Taqman® assay, HCV RNA, 559
coffee, HCV infection, liver fibrosis progression, 344
cognitive function, HCV infection, 312–314, 318
“cohesive ends” region, HBV DNA, hepatocellular carcinoma and, 169
co-infections, see also HIV infection
HBV, 87–88
antiviral treatment, 193
HDV with, 400, 406, 459, 461
combination therapy, de novo, 196–197
HCV infection, 373–375
recurrent hepatitis B prevention, 211
community-based cohort studies, liver fibrosis progression, 343
compensated cirrhosis, nucleos(t)ide analogs, HBV, 190
compensated noncirrhotic liver disease, nucleos(t)ide analogs, HBV infection, 190–191
compensation (financial), occupationally-acquired infection, 527
complement, 17
liver regeneration and, 6
compulsory vaccination policies, HBV, 517
computed tomography, hepatocellular carcinoma, 546
Convax (combination vaccine), 91
Con-1 genome, HCV, 329, 332
consensus sequence, HCV, 274
continuous venovenous hemofiltration, 480
contraception, protease inhibitors and, 369
covalescent phase, HAV infection, 36
stools, 44
convergence, virus evolution, 580
core gene variants, HBV, 136–138
convergence, virus evolution, 580
core promoter, HBV, 75–76, 128–130
mutations, 134–135
core proteins, see also nucleocapsid
HBV (HBc), 66, 67, 70–71, 76, 128, 129, see also HBcAg
hydrodynamically transfected mouse models, 182
pure positivity, 92
translation, 76–77
HCV, 224–226, 379, 380
hepatocellular carcinoma, 356
interaction with 5′ terminal UTR, 234
pre-C region, HBV, 222–226
C-terminal domain, HBV, 422
Hepatitis B virus, 419
Hepatitis C virus, 437
Hepatitis D virus, 407
Hepatitis E virus, 426
HBV vaccination, transgenic mouse models, 182–183
HCV and, 205, 207
protease inhibitors and, 208, 369
cysteine moieties, HBsAg, 108
cytomegalovirus
acute liver failure, 469, 477
children, 530, 531–532, 535
cytotoxic T lymphocyte-associated antigen 4, see CTLA4
cytotoxic T lymphocytes
HBV, variants, 138
as virus selection pressure, 577
woodchuck, assay, 102
Czech Republic, HCV, 260
daclatasvir, 374–375, 378, 385–386
damage-associated molecular patterns, 18, 19, 20
Dane particles, see HBV under virions
danoprevir, 373, 378, 383, 384
daycare centers, see also care facilities
HAV infection, 45
DDBI (protein subunit), HBs and, 167–168
DDX3 (DEAD box family RNA helicase), HCV and, 225
decompensated cirrhosis, recurrent hepatitis C, 208
decompensation, chronic hepatitis B, 149–150
decontamination, 567, 572–573
deer, HEV, 434
delayed virological response, 561
deletions, hepatocellular carcinoma, 169, 172
deletion variants (HBV)
core genes, 137–138
pre-S domains, hepatocellular carcinoma, 150
delta agent, see hepatitis D virus
dendritic cells, 15, 22
HBV vaccination, transgenic mouse models, 182–183
HCV and, 268–269, 270
Index
envelope proteins
HBV, 69, 75, see also surface proteins
oncogenesis, 169
translation, 77
HCV, 226–228
antibodies against, 269
as drug target, 386
transmembrane domains, 226, 233
Environmental Protection Agency, 565
environmental surfaces, see surfaces
enzyme immunoassays, HEV antibodies, 446
EOT (end of treatment) response, antiviral treatment, 364
Epaxal (hepatitis A vaccine), 50, 52
ephrin receptor A2, HCV binding and, 56
epitranscriptome, see also geography
genotypes, 580–581
HAV infection, 43–50, 57
HBV infection, 81–89, 581, see also
hepatocellular carcinoma, 163, 164–165
HIV infection, 494–495
vaccination on, 94
HCV infection, 246–265, 377, see also
migration
chronic viral hepatitis, 203–204
HAV infection, 498–499
trends, 258–263
HDV infection, 403–406
HEV infection, 431–436, 534, 581
polymorphisms, 155–156
epidermal growth factor receptors
HCV binding and, 227
HEV ORF3 protein and, 426
epidermal cell antibodies, 479
epiphenotypes
HAV cccDNA, 76, 79
hepatocellular carcinoma, 172, 357
‘e’ (encapsidation sequence), HBV, 128
Epstein–Barr virus
acute liver failure, 469, 477
children, 530, 535–536
eradications of virus, HCV, 364, 377,
560–561
erlotinib, 387
escape variants, see also immune escape
HAV, 110, 112, 113, 114, 116, 117, 119
ESCRPT pathway, HCV and, 225
esophageal varices, biomarkers for liver fibrosis, 348
ethanol injection, hepatocellular carcinoma, 548
ethnicity, HCV infection, treatment response, 367, 371, 372–373, 383
ethnic minorities, 508
ethylene oxide, 564, 568
Europe
HCV, 252, 260, 261
HAV, prevalence, 404–405
migrants, 507
European Consensus Group, HCV, guidelines, 525–526
evolution, 575–586, see also selection pressures
Avihepadnavirus genus, 99
constraints, 579–580, 583
HCV, fitness cost, 269–270, 275
HDV RNA, 396
exanthem subitum, 536
excitotoxicity, central nervous system, HCV infection, 319
exhaustion, T cells, 104, 276
exposure-prone procedures (EPP)
HBV, 516, 519, 524
HCV, 525
extended rapid virological response, 364, 561
extracellular matrix
liver fibrosis, 9
liver regeneration and, 8
extracorporeal liver support devices, 482
extrahepatic infection, 99
extrahepatic manifestations
HAV infection, 454–455
HBV infection, 85, 154–162, 457
HCV infection, 295–309, 463–464
central nervous system, 310–324
HEV infection, 445
eye, HBV, 160
eszemizime, 387
Fab224 antibody, binding to HEV, 428
factor V, 480
factor VII, 480
factor VIII, see also clotting factor
concentrates
antibodies, liver transplantation, 492
concentrates, HAV infection, 47
Fah knockout mouse, 182
famciclovir, HDV infection, 413–414
famciclovir, HDV infection, 454–455
HBV infection, 85, 154–162, 457
HCV infection, 295–309, 463–464
central nervous system, 310–324
HEV infection, 445
eye, HBV, 160
eszemizime, 387
Fab224 antibody, binding to HEV, 428
factor V, 480
factor VII, 480
factor VIII, see also clotting factor
concentrates
antibodies, liver transplantation, 492
concentrates, HAV infection, 47
Fah knockout mouse, 182
famciclovir, HDV infection, 413–414
family history
hepatocellular carcinoma, antiviral treatment, 191
fibrosis Probability Index, 345, 346
FibroScan®, 345
fibrometers, 345, 346
fibrinogen, HCV ORF3 protein and, 425
Fibroindex, 345, 346
fibrosis of liver, 9–10
HCV infection, 341–352
alcohol, 343, 463
chimpanzees vs humans, 284
cognitive function, 312
insulin resistance, 304
recurrent, 205
staging and progression, 341–344, 348
treatment response, 371
hepatocellular carcinoma, 354
HBV-HBV co-infection, 496
non-invasive assessment, 344–348
hemophilia, 488
treatment criteria, 191
fluorescence, see also geography
gene therapy, 195
fluorescence relocalization, HCV infection, 5
fluorescence, real-time polymerase chain reaction, 554
fluorescence relocalization, HCV infection, 5
fluorescence relocalization, HCV infection, 5
fluorescence relocalization, HCV infection, 5
flumazenil, 479
flumazenil, 479
fluorescence relocalization, HCV infection, 5
fluorescence relocalization, HCV infection, 5
fluorescence relocalization, HCV infection, 5
HCV, 295–309, 463–464
HBV infection, 85, 154–162, 457
HCV infection, 295–309, 463–464
central nervous system, 310–324
HEV infection, 445
eye, HBV, 160
eszemizime, 387
Fab224 antibody, binding to HEV, 428
factor V, 480
factor VII, 480
factor VIII, see also clotting factor
concentrates
antibodies, liver transplantation, 492
concentrates, HAV infection, 47
Fah knockout mouse, 182
famciclovir, HDV infection, 413–414
family history
hepatocellular carcinoma, antiviral treatment, 191
fibrosis Probability Index, 345, 346
FibroScan®, 345
fibrometers, 345, 346
fibrinogen, HCV ORF3 protein and, 425
Fibroindex, 345, 346
fibrosis of liver, 9–10
HCV infection, 341–352
alcohol, 343, 463
chimpanzees vs humans, 284
cognitive function, 312
insulin resistance, 304
recurrent, 205
staging and progression, 341–344, 348
treatment response, 371
hepatocellular carcinoma, 354
HBV-HBV co-infection, 496
non-invasive assessment, 344–348
hemophilia, 488
treatment criteria, 191
fluorescence, see also geography
gene therapy, 195
fluorescence relocalization, HCV infection, 5
fluorescence relocalization, HCV infection, 5
fluorescence relocalization, HCV infection, 5
flumazenil, 479
fluorescence, real-time polymerase chain reaction, 554
fluorescence relocalization, HCV infection, 337
Fln14 (transmembrane receptor), progenitor cell response model, 8
treatment criteria, 191
Fln14 (transmembrane receptor), progenitor cell response model, 8
food
HAV
outbreaks, 45
transmission, 46
virus survival, 43
HEV, 438
Food and Drug Administration, 565
formalin, virus inactivation, 568
hepatitis A vaccine, 51
HCV, 281
formulations, hepatitis A vaccines, 51–52
Forns Index, 345, 346, 348
“fossils”, 582–583
4-anilinoquinazolines, 388
FoxO1-dependent pathway, HCV and, 225
France
HAV, prevalence, 405
migrants, 509–510
French criteria, fulminant hepatitis, 478
fresh frozen plasma, 480
fulminant hepatitis, 468
children, 532
HAV, 454
genomes, 455
HBV, 132–133, 456–457
core gene variants, 136–137
HCV, 285
HEV, pregnancy, 476–477
liver transplantation, 478–479
non-A–E hepatitis, 535, 538
prognosis, 478–479
treatment, 479–482
futility, HCV infection treatments, 367–368
G145R mutation, HBV, 110, see also G145R variant
diagnosis and, 118
transmission, 117
G1896A substitution, HBV, 130, 132–133
G1856T mutation, HBV, 134
genomes, 455
gastric gland canaliculi, 136
GV viruses, 582
Gα
Gammagard accident, 249, 288
G1896A substitution, HBV, 130, 132–133
G1856T mutation, HBV, 134
genomes, 455
gastrointestinal tract
gankyrin, hepatocellular carcinoma, 357
gastrointestinal tract
HEV entry, 425
polyarteritis nodosa, 156
role in immune tolerance, 22
GBV viruses, 477, 582
classification, 221
HAV infection, 504
“GDD” motifs, NS5B protein, HCV, 231
gender
HCV infection, liver fibrosis, 343
progression, 343
HDV infection, cirrhosis, 407
HEV infection, 477
migrants, 511
genetic lineage tracing, tamoxifen-inducible, 5
genetics
HAV, 30–32, 34–35
hepatocellular carcinoma, 356–357
genetics (host), HCV infection
immune response, 267–269
treatment response, 371

genomes, see also open reading frames
detection and quantitation, 552–554
Hepadnaviridae, 97
HAV, 30–31, 34
fulminant hepatitis, 455
translation, 31–32
HBV, 66–69
circularization, 78
hepatocellular carcinoma and, 165–167
sequence analysis, 556, 557
surface protein encodings, 108–109
X domain, 166–168
HCV, 221–225, 379
assays, 559–562
CD8+ T cell epitopes, 274–275
Con-1 genome, 329, 332
discovery, 282
JC1 genome, transcomplementation system, 337–338
sequence analysis, 559–560
synonymous sites, 577
3′ terminal UTR, 235, 379
HDV, 395–398
HEV, 421–422
sequence analysis, 554–555, 556, 557, 559–560
genomewide association studies, drug development, 388–389
genotypes, 575–577, 579–581
HAV, 30, 35, 455, 576
epidemiology, 49
HBV, 88–89, 165–166, 459, 576
genotype G, 138
hepatocellular carcinoma, 89, 150
precore variants, 130
predictive value, 558
response to interferon, 195
HCV, 221–222, 464, 576
Europe, 261
genealogy, 579–580
hemophilia, 487
hepatocellular carcinoma, 354–355
interferon response, 206–207
Middle East, 262
treatment, 364, 560
treatment response, 206–207, 371
in vitro replication models, 333
world distribution, 263–264
HDV, 396
genealogy, 396, 403–404
HEV, 420–421, 464, 576–577
epidemiology, 432, 534
genotypic drug resistance, 198–199
genealogy, see also migration
evolution of viruses, 579–581
HAV, 47–48
vaccines and, 55–56, 57
HBV, 82, 83, 84, 534
a determinant mutations, 111
chronic viral hepatitis, 143
core gene variants, 136
genotypes, 88–89, 576
hepatocellular carcinoma, 164
MHR escape mutants, 112
HCV, 252–258, 259
HDV, genotypes, 396, 403–404
HEV, 432, 433
geranylgeraniol, 388
Germany
HCV, 261
HDV, prevalence, 404, 405
migrants, 509
germ cells, Hepadnaviridae integration, 99
Gianotti-Crosti syndrome, 159
gibbons, human hepatitis viruses, 581, 582
global prevalence
HAV, 82, 83
HCV, 252–258, 259
global programs, HBV vaccination, 93–94
glomerulonephritis
HBV, 158–160
HCV, 298, 463
gloves, 573
glucose-6-phosphate dehydrogenase deficiency, HEV and, 445
glutaraldehyde, 568, 571
glycophorin A, HAV hemagglutination, 34
Goteborg University Cirrhosis Index (GUCI), 345, 346
graft-versus-host disease, 470
growth, ground-glass-like hepatocytes, 119, 169
growth, interferon alpha on, 539, 542
growth factors, see also specific growth factors
liver regeneration, 6
signaling pathways, hepatocellular carcinoma, 357
Grp78 (chaperone), HEV binding, 426
GS-7777 (prodrug), 385, 386
GS-9256 (protease inhibitor), 373–374
guidelines
HBV
on healthcare workers, 520–521
treatment, 190, 474, 557–558
HCV, 525–526
postexposure prophylaxis, 518–519
H2 vaccine, HAV infection, 58
hairdressers
HBV, 516
HCV, 522
HALT-C model, 345, 346
hands, HAV survival, 43
HAVCR (HAV receptors), 33–34
HAV cellular receptor 1, 30
Havrix (hepatitis A vaccine), 50, 51
HBcAg, 128
anti-HBe-positive patients, variability, 140
chronic viral hepatitis, immune clearance phase, 144
immunogenicity, 71
HBeAg, 68, 128, 460–461
glomerulonephritis, 159
HDV and, 406
hepatocellular carcinoma, 164
immune tolerance, 128, 138, 184
persistence, 146
polyarteritis nodosa, 155
reversion, 148
seroconversion
chronic viral hepatitis, 132, 145–146, 149
core gene variants, 136
HBsAg variants and, 120
HBV genotypes, 88–89
HAV genotypes, 135, 138
nucleos(t)ide analogs, 196
polyarteritis nodosa, 157
transplacental transfer, 144
HBeAg-negative chronic liver disease, 130–132, 148, 456
genome sequence change, 577
treatment, 190, 191, 196
HBeAg-negative variants, treatment, 139–140
HBeAg-positivity, chronic viral hepatitis, 144–145
treatment, 190, 191, 194, 195, 196
HBV transmission, 516, 519
from healthcare workers, 520–521
perinatal, 534
treatment monitoring, 558
HBe proteins, 71
HBIG, see immunoglobulin
HBsAg, 69–70, 459, see also envelope proteins; surface proteins
after liver transplantation, 212
assays, 118, 184
blood transfusion, 117
chronic viral hepatitis, 456
immune-tolerant phase, 144
germicides on, 571
HDV therapy response, 411–412
germicides on, 571–572
chronic viral hepatitis, 144–145
blood transfusion, 117
after liver transplantation, 212
HCV infection, 251, 521,
thrombocytopenia
HCV infection, 249
hemofiltration, continuous venovenous, 480
HCV infection, 249
hemolysis
HEV infection, 445
ribavirin, 205, 206
hemopexin, HEV ORF3 protein and,
hemolytic anemia
hemophilia, 480–493
HCV, 249, 487, 488–489
hemorrhagic fever viruses, 477, 537–538
acute liver failure, 469
Hepadnaviridae, 65, 96–106, see also specific species
heparan sulfate proteoglycans
HCV binding, 227
HEV binding, 426
HepaRG cell line, 73
Hepascore®, 345, 346, 348
hepatectomy, 482, see also liver resection
hepatic encephalopathy, 479
cognitive function, HCV infection, 312–314, 318
hepatic progenitor cells, 3, 4, 7–8
hepatic stellate cells, liver regeneration, 6, 8
hepatitis A virus, 29–42
acute liver failure, 469
children, 453–454, 530, 533–534
acute liver failure, 538
epidemiology, 43–44, 45
vaccines, 51, 52, 54, 56, 57, 58
clinical features, 453–455, 471–472
diagnosis, 455
epidemiology, 43–50, 57
-genetic mechanisms, 30–32, 34–35
genotypes, 30, 35, 455, 576
epidemiology, 49
germicides on, 570
hemophilia, 487
HAV with, 87, 471, 472
HCV with, 87, 285
antiviral treatment, 193
occult, 457–458
HDV with, 87, 395, 399–400, 406, 459
antiviral treatment, 193
superinfection, 87, 104, 400, 406, 459, 461
hepatocellular carcinoma, see HBV infection under hepatocellular carcinoma
HIV infection, 85, 87–88, 494–498
antiviral treatment, 193
occult HBV infection, 457–458
life cycle, 65–66, 67, 72–79
liver failure, 85
acute, 469, 473
children, 538
-nucleos(t)ide analogs, 190, 473–474
liver transplantation, 209–212
children, 540
HIV infection, 498
mutants evolving, 113–114, 117, 119
prophylaxis, 91
migrants, 506–514
prevalence, 82
mutation rates, 128
occupational aspects, 86, 515–526
pathogenesis, 176–187
hepatitis B immunoglobulin (HBIG), liver transplantation, HDV infection, 414
hepatitis B virus, 127–130, see also HBV under carriers; HBV under chronic viral hepatitis; reactivation
assays, 555–558
children, see HBV infection under children
clinical features, 455–461, 472–474
complications, 84–85
core proteins, see HBV under core proteins
diagnosis, 459–461
DNA integration, 75
DNA transcription, 75–76
entry to cells, 73–74
epidemiology, 81–89, 581, see also migration
hepatocellular carcinoma, 163, 164–165
HIV infection, 494–495
vaccination on, 94
evolution, 127–130
extrahepatic manifestations, 85, 154–162, 457
-genotypes, 88–89, 165–166, 459, 576
-genotype G, 138
hepatocellular carcinoma, 89, 150
precore variants, 130
predictive value, 558
response to interferon, 195
germicides on, 570–572
hemophilia, 487
HAV with, 87, 471, 472
HCV with, 87, 285
antiviral treatment, 193
occult, 457–458
HDV with, 87, 395, 399–400, 406, 459
antiviral treatment, 193
superinfection, 87, 104, 400, 406, 459, 461
hepatocellular carcinoma, see HBV infection under hepatocellular carcinoma
HIV infection, 85, 87–88, 494–498
antiviral treatment, 193
occult HBV infection, 457–458
life cycle, 65–66, 67, 72–79
liver failure, 85
acute, 469, 473
children, 538
-nucleos(t)ide analogs, 190, 473–474
liver transplantation, 209–212
children, 540
HIV infection, 498
mutants evolving, 113–114, 117, 119
prophylaxis, 91
migrants, 506–514
prevalence, 82
mutation rates, 128
occupational aspects, 86, 515–526
pathogenesis, 176–187
-hepatitis B immunoglobulin (HBIG), liver transplantation, HDV infection, 414
-hepatitis B virus, 127–130, see also HBV under carriers; HBV under chronic viral hepatitis; reactivation
-assays, 555–558
-children, see HBV infection under children
-clinical features, 455–461, 472–474
-complications, 84–85
-core proteins, see HBV under core proteins
diagnosis, 459–461
-DNA integration, 75
-DNA transcription, 75–76
-entry to cells, 73–74
-epidemiology, 81–89, 581, see also migration
-hepatocellular carcinoma, 163, 164–165
-HIV infection, 494–495
-vaccination on, 94
evolution, 127–130
-extrahepatic manifestations, 85, 154–162, 457
-genotypes, 88–89, 165–166, 459, 576
-genotype G, 138
-hepatocellular carcinoma, 89, 150
-precore variants, 130
-predictive value, 558
-response to interferon, 195
-germicides on, 570–572
-hemophilia, 487
-HAV with, 87, 471, 472
-HCV with, 87, 285
-antiviral treatment, 193
-occult, 457–458
-HDV with, 87, 395, 399–400, 406, 459
-antiviral treatment, 193
-superinfection, 87, 104, 400, 406, 459, 461
-hepatocellular carcinoma, see HBV infection under hepatocellular carcinoma
-HIV infection, 85, 87–88, 494–498
-antiviral treatment, 193
-occult HBV infection, 457–458
-life cycle, 65–66, 67, 72–79
-liver failure, 85
-acute, 469, 473
-children, 538
-nucleos(t)ide analogs, 190, 473–474
-liver transplantation, 209–212
-children, 540
-HIV infection, 498
-mutants evolving, 113–114, 117, 119
-prophylaxis, 91
-migrants, 506–514
-prevalence, 82
-mutation rates, 128
-occupational aspects, 86, 515–526
-pathogenesis, 176–187
-
hepatitis C virus, 282, 596
hepatitis B virus (continued)
precore variants, 130–133
detection methods, 140
response to interferon, 139
prevention, see HBV infection under prevention
proteins, 69–72
protein translation, 76–77
reactivation, immunosuppressive therapy, 192, 456–457, 458
recombinant viruses, 579
replication, 77–78
"illegitimate", 66–67, 74
interference by HDV, 400
HBV with, 87, 285
HAV with, 472
HDV and, 406
hepatocellular carcinoma, see HCV infection under hepatocellular carcinoma
hypervariable regions, 578, see also hypervariable region (HVR1)
immune response, 266–279, 282, 284
central nervous system, 319
failure, 272–277, 288–289
in vitro models, 325–340
life cycle, 378–379, 381–382
liver transplantation, 203–209, 542
from grafts, 249
HIV co-infection, 503–504
treatment, 372
migration, 506–514
prevalence (Europe), 261
natural history, 282–285
nonstructural proteins, 222, 228–233, 325–326, 356, 379, 380, see also ORF1 nonstructural proteins
occupational aspects, 521–526
origins, 581
recombinant viruses, 579
replication, see HCV under replication sequence drift, 577
structure, 221–228, 233–235, 282
treatment, 362–376, 560–561
drug development, 377–391
factors on response, 370–372
patients to treat, 370
special populations, 372–373
hepatitis D antigen, 396–397
hepatitis decompensation, chronic hepatitis B, 149–150
hepatitis D virus, 476
acute liver failure, 469, 476
animal models, 280–294
antiviral agent development, 291
assays, 559–562
brain-specific variants, 319
cell cultures, 325–340
children, 530, 540–542
treatment, 373
chronic viral hepatitis, see HCV under chronic viral hepatitis
clinical features, 461–464, 475–476
diagnosis, 464
epidemiology, 246–265, 377, see also migration
chronic viral hepatitis, 203–204
HIV infection, 498–499
trends, 258–263
evolution, 577–580
extrahepatic manifestations, 295–309, 463–464
central nervous system, 310–324
fibrosis of liver, see HCV infection under fibrosis of liver
genome, see HCV under genomes
genotypes, see HCV under genotypes
hemophilia, 249, 487, 488–489
HAV with, 472
HBV with, 87, 285
antiviral treatment, 193
occult, 457–458
HDV and, 406
hepatocellular carcinoma, see HCV infection under hepatocellular carcinoma
hypervariable regions, 578, see also hypervariable region (HVR1)
immune response, 266–279, 282, 284
central nervous system, 319
failure, 272–277, 288–289
in vitro models, 325–340
life cycle, 378–379, 381–382
liver transplantation, 203–209, 542
from grafts, 249
HIV co-infection, 503–504
treatment, 372
migration, 506–514
prevalence (Europe), 261
natural history, 282–285
nonstructural proteins, 222, 228–233, 325–326, 356, 379, 380, see also ORF1 nonstructural proteins
occupational aspects, 521–526
origins, 581
recombinant viruses, 579
replication, see HCV under replication sequence drift, 577
structure, 221–228, 233–235, 282
treatment, 362–376, 560–561
drug development, 377–391
factors on response, 370–372
patients to treat, 370
special populations, 372–373
hepatitis D antigen, 396–397
hepatitis decompensation, chronic hepatitis B, 149–150
hepatitis D virus, 476
acute liver failure, 469, 476
assays, 562
children, 406, 530, 542
disinfection, 572
epidemiology, 403–406
genome, 395–398
HBV with, 87, 395, 399–400, 406, 459
antiviral treatment, 193
superinfection, 87, 104, 400, 406, 459, 461
HIV infection, 504
prevalence, 404
life cycle, 398–400
natural history, 406–407
occupational aspects, 526
replication, 398–399, 410
serology, 461
transmission, 453
treatment, 410–416, 476
efficacy, 412–414
vaccination, 104
hepatitis E virus, see also avian HEV
acute liver failure, 443–444, 469, 476–477
assays, 562
children, 534–535
disinfection, 419–420, 572
epidemiology, 431–436, 534, 581
genome, 421–422
hepatitis E virus, 476
acute liver failure, 469, 476
assays, 562
children, 534–535
disinfection, 419–420, 572
epidemiology, 431–436, 534, 581
genome, 421–422
hepatitis G virus, see GBV viruses
hepatitis splenomegaly syndrome, chickens, 434–435
hepatocellular carcinoma
Avihepadnavirus genus, 100
diagnosis, 545–546
family history, antiviral treatment, 193
HBsAg variants, 117
hepatitis B vaccination on epidemiology, 94
HBV infection, 85
chronic viral hepatitis, 150, 151, 164
genotypes, 89, 150
oncogenesis, 163–175
HCV infection, 353–361
hemophilia, 489–490
HIV infection, 499–500
liver stiffness and, 348
steatosis, 304
HDV infection, 400, 407
management, 544–551
originating cells, 3–4, 8–9
response assessment, 549–550
staging, 546–547
subclasses, 172
hepatocyte nuclear factor 1, binding site, HBV, 134
hepatocyte nuclear factor 4, HEV ORF3 protein and, 424
hepatocytes
as antigen-presenting cells, 277
ground-glass-like, 119, 169
HEV infection, 446
immortalization
HBV, 170
by HCV core protein, 226
liver regeneration, 5
primary, HCV infection, 336–337
transplantation of, 482
turnover, 100
hepatoma cell lines, see also human hepatoma 7 cells
HBV study, 73
hepatorenal syndrome, liver transplantation, 211
Hepatitis virus, 420–421
herd immunity, hepatitis A vaccination, 56, 60
heron HBV (HHBV), 98
herpes simplex virus
acute liver failure, 469, 477
children, 530, 535
intrauterine liver infections, 531
neonates, 532–533
herpes viruses, children, 535–536
HEV239 vaccine, 424
Hh signaling, progenitor cell response
model, 7
high-density lipoprotein, HCV and, 273
high-dose HBIG, recurrent hepatitis B prevention, 210
high-dose ribavirin, 364
high-level disinfection, 566
high-throughput screening, drug development, 386, 389
Hippo pathway, liver regeneration
historical aspects
histological activity, HCV infection, liver regeneration
HMG-CoA reductase, 380
HLA alleles
historical aspects
histological activity, HCV infection, liver regeneration
histone deacetylase, hepatocellular carcinoma and, 357
historical aspects
HAV, 29–30
HCV, 247, 280–282
HEV, 442
HIV infection
children, 536–537
hemophilia, 487
HCV infection, 490, 491, 492
HAV infection, 494
vaccine response, 52–53
HAV infection, 85, 87–88, 494–498
antiviral treatment, 193
occult, 457–458
HCV infection, 252, 463, 498–504
brain MR3, 315
cognitive impairment, 313–314
hemophilia, 490, 491, 492
liver fibrosis progression, 344
perinatal transmission, 252
treatment, 372
HDV, 504
prevalence, 404
intrauterine, 531
neonates, 532
zoones, 582
HLA alleles
HBV infection, 154–155
HCV immune escape, 578
HM175 strain, HAV, 50
HMG-Co-A reductase, 380
inhibitors, 388
HNF4 (transcription factor), HBV, 76
homeostatic model assessment insulin resistance (HOMA-IR), HCV infection, 303–304
homosexual activity, see men who have sex with men
horses
HEV, 436
hepatitis viruses, 582
host cell permissiveness, in vitro replication models, HCV, 333–336
host-targeted antivirals, HCV infection, 375, 387–388
household contacts
HBV, 82–83
HCV, 252
human brain endothelial cells, HCV replication, 336
human chimeric mouse models
HBV infection, 181, 182
HCV infection, 289–291
human hepatocytes (primary), HBV culture, 72–73
human hepatoma 7 cells (HuH7 cells)
HCV replication, 331, 333, 334, 336
HCV study, 222–223
human herpes virus, 6, 477
children, 536
intrauterine liver infections, 531
human immunoglobulin, see normal human immunoglobulin
humanized mouse, HCV infection, 291
human parechoviruses, 533
human telomerase reverse transcriptase gene (hTERT gene), HBV DNA insertions, 170
hybrid capture, genome detection, 552–553
hydrodynamically transfected HBV mouse models, 179–182, 183–184
hydrogen peroxide, 568
hygiene
hepatitis A prevention, 50
HBV and, 83
hyperacute hepatitis, 469
hyperbilirubinemia, see also jaundice
atazanavir, 501
hyperthermia, acute liver failure, 470
hypervirulent region (HVR1), HCV, 227, 269–270, 284–285, 288–289
extrahepatic replication and, 316
hypervirulent regions (HVR)
HCV, 423–424, 578
virus evolution, 577, 578
hyperventilation, 479
hypoglycemia, 480
hypothermia, 479
hypothyroidism, HCV infection and, 307
hypoxia-inducible factor 1 alpha (HIF1α), 168
iatrogenic spread, see also blood transfusion; hemodialysis; nosocomial infection
HCV infection, 246, 247, 260, 524–526
IFN regulatory factor, 3, 37
IFN sensitivity determining region, HCV NS5A, 232
IgG anti-HBc, 459, 460
IgG anti-HEV, 446
IgM anti-HAV, 36, 455
IgM anti-HBc, 459, 460
IgM anti-HD, 411
IgM anti-HEV, 446
IL28B SNPs, see also interleukin-28B gene
HCV infection, 362
CC genotype, 206–207
IFN’  𝜆 and, 388–389
treatment response, 371, 490
treatment timing, 475
“illegitimate replication”, HBV, 66–67, 74
ILLUMINATE trial, HCV infection, 365
immortalization of hepatocytes
HBV, 170
HCV core protein, 226
immune clearance phase, chronic HBV infection, 144–146, 456
immune complexes
HBV infection
acute hepatitis, 155, 156
glomerulonephritis, 158, 457
transverse myelitis, 457
urticaria, 159
HCV infection, central nervous system, 310–311
immune escape, 580
HAV, 37
HBV, 113, 114, 116
HCV, 273–275, 578
immune reconstitution, HAART, HBV infection, 87
immune reconstitution inflammatory syndrome, 498
immune response
HBV
extrahepatic manifestations, 154–155
transgenic mouse models, 177–178, 183–184
variants, 138
HAV, 266–279, 282, 284
central nervous system, 319
treatment, 272–277, 288–289
HDV, 400, 411
HEV ORF3 protein and, 424
immune tolerance, 13, 22, see also tolerogenic environments
children, 539
HBsAg, 128, 138, 184
HBV transgenic mouse models, 177, 179, 182–183
immune tolerant phase
chronic viral hepatitis, HBV infection, 144, 191, 456
immunity (protective), HCV, 285–289
immunocompromise, see also immunosuppressive therapy
HBV
children, 540
core deletion variants, 137–138
hydrodynamically transfected mouse models, 179–180
vaccination, 91
immunodecient animal models, see also chimeric mouse models
HBV infection, 291
immunogenicity
HBsAg, 71
hepatitis A vaccines, 52–53
magnetic resonance imaging, see also proton magnetic resonance spectroscopy
hepatocellular carcinoma, 546
major B cell epitope, HBsAg, 108
major histocompatibility complex
HBV, core gene variants and, 136
HCV and, 268–269, 275
major hydrophilic region (MHR), HBsAg, 107, 109, 110, 112
malaria, 470
male gender
HCV infection, liver fibrosis progression, 343
HDV infection, cirrhosis, 407
HEV infection, 477
malignant disease, see also cancer stem cells; hepatocellular carcinoma; lymphoma
HCV infection, 307
cholangiocarcinoma, 358
liver infiltration, 470
lymphoproliferative disease (EBV-related), liver transplantation, 536
mandatory vaccination policies, HBV, 517
Manhattan HIV Brain Bank, HCV and cognitive impairment, 313
mannitol, 479
manufacture
hepatitis A vaccines, 51
immune globulin, 59
markers (biomarkers), fibrosis of liver, 345, 346, 348
maternal-neonatal transmission, see perinatal transmission
maturation cleavage, HAV, 45
MC syndrome, 297–298
measles, 535
meat, HEV, 438
median expected time to cirrhosis, 342–343
MELD score, 478
Mele, A. et al. (Italian Association for the Study of the Liver), 525
Meltzer triad, 297
membranous glomerulonephritis
HBV infection, 159–160
HCV infection, 298, 463
membranous web, HCV, 326, 379
men who have sex with men, see also homosexual activity
HAV infection, 45, 46
HBV infection, 86
HCV infection, 252
HIV infection, 498–499
mercitrabine, 373, 378, 385, 386
Merlin (Nf2 gene product), liver regeneration and, 8
metal ion ligand-binding site (MILBS), HAV receptor, 34
metalloproteinases, HBV transgenic mouse models, 178
METAVIR score, fibrosis staging, 342
metformin, HCV infection, insulin resistance, 305
methadone, HCV infection and, 373
methylation, HDAg, 397
methylation abnormalities, hepatocellular carcinoma, 172
Mexico, HCV, 260
mice, see murine models
microaneurysms, renal vasculitis, 158
microarray screening, hepatocellular carcinoma, 172
microglia, HCV, 318, 319
microRNA(s)
hepatocellular carcinoma, 172–173
liver regeneration, 6
microRNA-122 (HCV target), 234, 325, 336, 380
antagonists, 387
microspheres (DEB TACE), hepatocellular carcinoma, 549
microutubules, HEV ORF3 protein and, 425
midazolam, telaprevir and, 369
Middle East, HCV, 262–263
migration
HBV, 82, 506–514
HCV, 261, 506–514
on HDV prevalence, 404
Milan criteria, hepatocellular carcinoma, 548
minichromosomes, viral, 75
minimal encephalopathy, 312
minus-strand DNA, HBV, synthesis, 77
miravirsen, 375, 387–388
mitochondrial antiviral-signaling protein (MATS), 20, 272
fragment with MS3 cleavage site, 337
HCV nonstructural proteins and, 230–231
mixed cryoglobulinemia, HCV infection, 296–302, 463
central nervous system, 310–311
modified vaccinia Ankara boost vaccination, 104
moist heat, sterilization, 568
molecular biology diagnostic techniques, 552–563
variability of viruses, 583
molecular clock analysis, MSM-specific HCV, 252
molecular epidemiology, HAV infection, 49
molecular hepatocarcinogenesis, HCV infection, 354–356
molecular hybridization, probe–DNA complexes, HBV, 461
Mongolia, HDV, 406
mongoose HEV, 436
monoclonal antibodies
HEV ORF proteins, 447
host-cell receptors, HCV, 289–291
liver transplant patients, HBsAg mutants evolving, 113–114
monoclonal HCV infection, chimpanzees, 284–285
monocyte chemotractant protein-1, 17
monocytes, 14
HCV, 266
mononuclear cells, see also peripheral blood mononuclear cells
neonates, 184
morphologic alteration and disintegration test (MADT), 571
mortality
HAV infection, 35, 471
HBV infection
chronic hepatitis, 85, 150, 456
HIV infection, 496
HCV infection
hemophilia, 489
HIV infection, 500
HIV infection, 443
pregnancy, 444
mouse, see murine models
mouse cell lines, HCV, 336
MP3 (liver fibrosis biomarker), 345, 346
M protein, HBV, 69, 70
mRNA
HBV core gene variant, 138
precore, 129
HDV replication, 399
MS-1 sera, 30
mucin region, HAV receptor, 34
multidrug resistance, HBV, rescue therapy, 199
multiple sex partners, HBV infection, 86
multivesicular bodies, HBV infection, 78
murine models
HBV infection, 73, 176–187
treatments, 182–183
HCV infection, 289–291
mutations, see also specific mutations
drug resistance, 197–198, 578
HBV
core genes, 138
drug resistance, 578
rates, 128
HCV
cell culture adaptation, 331–333
drug resistance, 384
monoclonal infection, 284, 285
HEV capsid protein, 424
myc family genes, woodchuck hepatitis virus and HCC, 170
myeloid dendritic cells, 15, 270
myofibroblasts, 9
myo-inositol (ml), central nervous system, HCV infection, 314
Myxcludex-B, 414
N236T mutation, drug resistance, 198
N-acetylaspartate (NAA), central nervous system, HCV infection, 314
N-acetyl cysteine, 479
National Health and Nutrition Examination Survey (NHANES), hepatitis B prevalence, 82
Native Americans
hepatitis A prophylaxis, 55
HCV, 259
natural boosting, maternal, HBV, 93
natural killer cells, see NK cells
needlestick injury, see also inoculation injuries
HCV, 251, 523
negative effector of transcription, duck hepatitis virus, 76
negative-strand RNA
HAV, 34–35
HCV, detection, 316–317
HEV, 426
neomycin-phosphotransferase gene,
HCV replicon, 329
neonatal intensive care units, see also perinatal transmission
hepatitis A outbreaks, 45–46
neonates, 529–533
HBeAg, 128, 144
hepatitis A vaccine response, 52, 54
hepatitis B vaccine, 93
mononuclear cells, 184
nephropathy, see also renal dysfunction
HBV infection, children, 159
HCV infection, 298
nephrotic syndrome, HCV infection, 463
nephrotoxicity
antiviral agents, 211–212
nucleos(t)ide analogs, 211–212
antibodies
acute liver failure, 577–578
HBV replication, 495–496
HDV on, 400
HCV core protein and, 225–226
JFH1 replicon, 332
NS2, HCV, 232–233
NS3 protease-helicase, 373,
NS3 NTPase, HCV, 229–230
NS5B polymerase, 373,
NS5A protein, HCV, 231–232
NS4A, 386
NS4B, HCV, 233, 258–259
NS5A inhibitors, second wave, 383
NS helicase, 229–230
HCV genome, 221, 224–225
NS3/NS4A protease, HCV, 228–229,
356
NS3 NTPase, HCV, 229–230
NS3 protease-helicase, 373, 374,
379–382
NS4A, 380
on NS3 binding, 230
NS4B, HCV, 233, 258–259
NS5A gene (HCV)
antiviral treatment on, 577–578
hypervariable region, 577
NS5A inhibitors, 374–375
385–386
daclatasvir, 374–375
378, 385–386
NS5A protein, HCV, 231–232
326, 356, 379, 380, 385
NS5B polymerase, 373, 374
NS5B protein
HCV, 231, 232
380
JFH1 replicon, 332
NS5B RNA-dependent RNA polymerase inhibitors, 384–385
nuclear factor kappa-light-chain-enhancer of activated B (NF-κB)
HCV core protein and, 225–226
HDV on, 400
HIV and, 495
liver regeneration, 6
nuclear localization sequence, HBV, 74
nuclear receptor binding site, HBV, effect of double BCP mutation, 134
nucleic acid technologies, blood donor screening, 248
nucleocapsid, see also core proteins
HBV, 66, 67, 70, 78
nucleos(t)ide analogs (NUCs), see also lamivudine
HBV infection, 194, 195–196, 558
acute liver failure, 473–474
adverse events, 196
breast milk, 193
compensated noncirrhotic liver disease, 190–191
glomerulonephritis, 159
lactic acidosis, 196, 212
life-threatening liver disease, 189–190
polyarteritis nodosa, 157
prophylaxis, 458
recurrence prevention with HBIG, 210, 211
regimens, 196
resistance, 197–199
response predictors, 196
HCV infection, 375
nucleos(t)ide inhibitors, 384–385
mercaptamine, 373, 378, 385
null responders, antiviral treatment, 364, 369
obesity, transient elastography and, 347
occludin, HCV binding, 227–228
extrahepatic cells, 318
occult HBV infection, mixed carriers
hepatocellular carcinoma, 164
occult HCV infection, mixed cryoglobulinemia, 301
occupational aspects, 515–528
HAV, 526
HBV, 86, 515–526
HCV, 521–526
HDV, 526
HEV, 526–527
Oceania
HCV, 258–259
Pacific islands, HDV, 406
ocular manifestations, HBV, 160
oligoprobes, 552–553
HBV variants, 140
oncogenesis, HBV, 163–175
oncogenic viruses, 173
open reading frames (ORF)
Hepadnaviridae, 97
HAV, 30, 31
HBV, 67–69
128
coding for Pol, 71
for HBsAg, 108
HCV, 221, 222, 224, 325
HEV, 419, 421–425
virus evolution, 580
operative procedures, HBV transmission, 516
oral-fecal route, HAV, 37
oral lichen planus, 159–160
orangutans, human hepatitis viruses, 581, 582
recombinant proteins, HEV antibody immunoassays, 446
recombinant viruses, 579, see also chimeric viruses
HEV, 421, 579
recurrent hepatitis B, 209–212
recurrent hepatitis C after liver transplantation, 204–208
prevention, 208–209
recurrent hepatitis D, 406
refuges, 507
regeneration (liver), 3–8, 100
regenerative nodules, chronic viral hepatitis, 8, 9f
regulation, germicides, 565
regulatory signals, HBV genome, 166
regulatory T cells, 21
HAV infection, 36, 37, 38–39
HBV and, 272, 276–277
rejection of liver transplant corticosteroids, 205
interferon, 205
rejuvenation, T cells, 103
relapse
HAV infection, liver transplantation, 454, 472
HAV infection, 364
relapsing hepatitis, HAV infection, 454
release of virions, HAV, 35
renal dysfunction, see also membranous glomerulonephritis; nephropathy
HAV infection, 454–455
HBV infection, 457, 480
liver transplantation, 211–212
HBV infection, Peg-IFN/RBV treatment, 370
renal vasculitis, HBV and, 158
repeat sequences, see also direct repeats, HBV integration, 169
replication,
Hepadnaviridae, 97
animal models, 100
extrahepatic, 99
HAV, 34–35
HBV, 77–78
“illegitimate”, 66–67, 74
interference by HDV, 400
HBV, 222–223, 325–327
in cell lines, 329
cured cells, 331, 336
cyclophilins, 231–232
extrahepatic, 316–317
human brain endothelial cells, 336
human hepatoma 7 cells, 331, 333, 334, 336
peripheral blood mononuclear cells, 337
permissiveness, 333–336
T cells and, 337
HDV, 398–399, 410
HAV, 425, 425–427
replicative phase, chronic viral hepatitis B, 456
replicons, see also subgenomic replicons; specific replicons
HBV, 222
chimeric, 332, 333, 334–335
transfection in cell lines, 329, 338
rescue therapy, antiviral drug-resistant HBV, 199
residual phase (inactive phase) chronic viral hepatitis, HBV infection, 146–148, 456
resistance-associated amino acid variants (RAVs), HCV, 369, 375
direct-acting antiviral agents and, 372
resistance to drugs, see drug resistance to gemcides, 569–570
HBsAg, 571
resolution of infection
histology, 100
woodchuck hepatitis virus, 100
respiratory failure, 480
RESPOND-2 trial, HCV infection, 367, 383
Response Evaluation Criteria in Solid Tumors (RECIST), 549–550
response-guided antiviral therapy (RGT), 207
HCV, 364, 367–368
retention enaneta, 479
retinoblastoma pathway, hepatocellular carcinoma and, 357
retinoic acid-inducible gene 1 protein, HCV nonstructural proteins and, 230
retinoic acid receptor genes (RARs), HCV, 369, 375
protease inhibitors and, 369, 384
drug interactions, 491
protease inhibitors and, 369, 384
rituximab
antiviral treatment and, 192
HCV infection, mixed cryoglobulinemia, 301–302
RNA
HAV, 166
HBV, 316–318, 464, see also negative-strand RNA
HIV infection, 501–503
mixed cryoglobulinemia, 300
monitoring, 561
HCV RNA, 316–318, 324–350
plus-strand RNA, 327
HIV infection, mixed cryoglobulinemia, 301–302
RNA-dependent RNA polymerase, see NS5B protein
RNA-dependent RNA polymerase inhibitors, 384–385, 386
RNA helicases, 20, 225, 356
RNA polymerases, HDV replication, 399
RNA replicons, HCV, 222
road map approach, antiviral treatment, 198
rodent models, see also murine models
HAV infection, 39
HCV infection, 290, 291
rolling-circle mechanism, HDV replication, 410
Roma people, 507, 509
roseola infantum, 536
rubella, 530, 531
rural-to-urban migration, 506–507
Russia
HCV, 260
HDV, prevalence, 405
S282T (resistance mutation), HCV, 385
salvage therapies, antiviral drug-resistant HBV, 199
sampling error, liver biopsy, 342
Sanger method, PCR amplicon sequencing, 554
scavenger receptor class B type 1 (SR-B1), 227, 289–291, 329
extrahepatic cells, 318
immune escape, 273
inhibitor (ITX 5061), 386–387
schistosomiasis, mass treatment programs, HCV, 250, 262
screening, see also surveillance
HBV, 84
HCV, 248
healthcare workers, HCV, 525, 526
SCY-635 (cyclophilin inhibitor), 387
seasonal peaks, HAV infection, 49
second generation protease inhibitors, 384
second wave NS3/4A inhibitors, 383
self-efficacy, migrants, 511
sequence analysis of genomes, 554–555, 556, 557, 559–560
HAV, 455
HBV, 556, 557
HCV, 559–560
sequence drift, HCV, 577
seroconversion, see also seroconversion under HBeAg
anti-HBs, polyarteritis nodosa, 157
protein, 282
serological window, 459
serology
acute hepatitis, 471
HAV, 32–33, 455
prevaccination testing, 58
HBV, 459–461
postvaccination testing, 92
HCV, 464
MC syndrome, 298
HDV, 461
HEV, 446, 465
seroprevalence of HAV infection, 47–49
vaccines and, 55
serum sickness-like syndrome, HBV, 456
70S particles, hepatitis A vaccines, 50–51
severe acute hepatitis, 468
HBV, treatment, 473, 474
severity, perceived, 510–511
sewage workers, HAV, 526
sexual contact, see also men who have sex with men
HAV infection, 86, 90
HIV infection, 495
HCV and, 252
sex work, migrants, 510
SF-36 questionnaire, health-related quality of life, 311
sG145R variant, HBsAg, 119
S gene, deletions, hepatocellular carcinoma and, 169
SHARP trial, hepatocellular carcinoma, 547
shear wave velocity, 346, 347
sheep, HEV, 436
shellfish
HAV, 46
HEV, 582
shock
acute liver failure, 470
splanchnic vasodilatation, 480
sicca-like symptoms, HCV infection, 298
signal amplification, genome detection, 552–553
signaling pathways, see also specific pathways
growth factors, hepatocellular carcinoma, 357
liver regeneration, 6
signal transducer and activator of transcription 3 (STAT3), liver regeneration, 6
simeprevir, 383, 384
single nucleotide polymorphisms chromosome 19, interferon response, 206–207
chromosome 20, ribavirin-induced hemolysis and, 206
hepatocellular carcinoma and, 357
sinusoidal obstruction syndrome, 470
skin, see cutaneous manifestations
SKI/SIP, lipid metabolism, 224
SL9266, HCV genome, 235
slow responders, antiviral treatment, 364, 368
sMaf proteins, HCV nonstructural proteins and, 230
small HDAg, 396, 397
small hepatitis B surface protein (SHBs), 69–70
small-molecule inhibitors, HCV, 382
Sm-D1, HCV NS3 protein and, 230
smoke, see also hepatitis
progenitor cells, 9
stem-loops
I, II and IV, HCV IRES, 234
HEV, 422
sterility assurance level, 565–566
sterilization, 564–574
definitions, 565–567
methods, 568
sterol regulatory element-binding protein-1c, HCV NS5A and, 232
stools, see feces
stop signals, HBV cccDNA transcription, 76
storage, vaccines, HAV, 52
streamed liver hypothesis, 4–5
stromal cell-derived factor 1 (SDF1), progenitor cell response model, 7
subacute hepatitis, 469
subgenomic replicons
HAV cell line transfection, 329–331
HEV, 426–427
subgenotypes, HBV, 88
Sub-Saharan Africa, migrants from, 509
substance abuse, see drug users; injection drug use
subviral particles, HBV, 69, 78
sulfonlurea, HCV infection, 305
sumoylation, HDAg, 397
superinfection
HDV on HBV, 87, 104, 107, 406, 459, 461
HCV, 285–289
HAV infection, 499
suppressor of cytokine signaling 3 (SOCS3)
HCV infection, type 2 diabetes mellitus, 303
liver regeneration inhibition, 6
surface proteins, HBV, 69–70, see also envelope proteins; HBsAg
drug resistance, 197
encodings, 108–109
SPRINT trials, HCV infection, 366–367
S protein, see also large S protein, HBV, 69, 70
sR145 variants, HBsAg, diagnosis, 118
SREBPs, lipid metabolism, 224
stability, vaccines, HAV, 52
staging
hepatocellular carcinoma, 546–547
liver fibrosis, 341–344
statins, 388
stavudine, drug interactions, 501
steam, sterilization, 568
steatosis, HCV infection, 282–289
carcinogenesis, 355
insulin resistance, 304
NS4B and, 233
treatment response, 371
stellate cells, liver regeneration, 6, 8
cell maturation arrest, hepatocellular carcinoma, 8
cancer stem cells, 9
sterinease, 567
I, II and IV, HCV IRES, 234
HEV, 422
sterility assurance level, 565–566
sterilization, 564–574
definitions, 565–567
methods, 568
sterol regulatory element-binding protein-1c, HCV NS5A and, 232
stools, see feces
stop signals, HBV cccDNA transcription, 76
storage, vaccines, HAV, 52
streamed liver hypothesis, 4–5
stromal cell-derived factor 1 (SDF1), progenitor cell response model, 7
subacute hepatitis, 469
subgenomic replicons
HAV cell line transfection, 329–331
HEV, 426–427
subgenotypes, HBV, 88
Sub-Saharan Africa, migrants from, 509
substance abuse, see drug users; injection drug use
subviral particles, HBV, 69, 78
sulfonlurea, HCV infection, 305
sumoylation, HDAG, 397
superinfection
HDV on HBV, 87, 104, 107, 406, 459, 461
HCV, 285–289
HAV infection, 499
suppressor of cytokine signaling 3 (SOCS3)
HCV infection, type 2 diabetes mellitus, 303
liver regeneration inhibition, 6
surface proteins, HBV, 69–70, see also envelope proteins; HBsAg
drug resistance, 197
encodings, 108–109
Index 605
surrogate endpoints, HBV treatment, 189
surgery, HBV transmission, 516
surrogates, HBV, 369
surveillance, see also screening
hepatocellular carcinoma, 490, 545–546
sustained virological response, HCV, 364, 377, 560–561
swine HEV, 432–433, 438
syringes, HCV transmission, 250, 251
T3 motif, HBV, 77
tacrolimus, 205, 208, 369
taiwan
hepatitis B vaccination, 94, 538
HDV, 406
tamoxifen-induced genetic lineage
tracing, 5
target amplification methods, genome
detection, 553–554
taribavirin, 206
tattooing, HCV and, 251
t cell (s), 16, 20–21, 22, see also specific
types
exhaustion, 104, 276
HBV infection, animal models, 178–179, 184
HCV infection, 271–272
chimpanzees, 289
evans, 273–277
exhaustion, 276
transient replication systems to
study response, 337
virus replication, 337
PDL1-programmed cell death 1
ligand 1, 103–104
viral load on, 103
woodchuck, 101–102
assay, 102
T cell epitopes, HBV, mutants evolving, 116, 136
T cell immunoglobulin mucus, see
HAVCR
T cell protein tyrosine phosphatase, HCV
nonstructural proteins and, 231
tegobuvir, 385, 386
telaprevir, HCV infection, 363, 364–366, 378, 382, 384
chimeric mouse models, 291
combination therapies, 374
drug interactions, 491
drug resistance, 369
HIV co-infection, 372, 503
mixed cryoglobulinemia, 302
molecule, 383
monitoring, 561
recurrent hepatitis, 208
toxicity, 368–369
telbivudine, HBV infection
acute liver failure, 473–474
adverse events, 196
children, 540
drug resistance, 198, 199
HBcAg-positive chronic viral hepatitis,
194
pregnancy, 192
temperatures, chemical sterilization, 569
template switches, HBV, DNA synthesis,
77–78
temporal patterns, hepatitis A
epidemiology, 49
tenofivir (TDF)
HBV infection, 473, 558
acute-on-chronic liver failure, 474
children, 540
entecavir with, 197
HBcAg-positive chronic viral hepatitis,
194
HIV co-infection, 497–498
immunosuppressive therapy and, 192
nephrotoxicity, 196
pregnancy, 90, 193
recurrence prevention, 211
renal impairment, 211–212
rescue therapy for drug resistance,
199
virus variants and, 140
women of reproductive age, 192
HCV infection, protease inhibitors and,
369
teratogenicity
interferon, 192
lamivudine, 193
PEG-IFN/RBV treatment, 370
termin protein, HBV, 67
ORF coding for Pol, 71
Th17 T cells, 21
T helper cells
HBcAg on, 144
HBV transgenic mouse models, 179
woodchuck, 102
thiopental, 479
3C+ (protein), HAV, 32
5′ terminal UTR, HCV genome, 235, 379
threshold cycle, real-time polymerase
chain reaction, 554
thrombocytopenia
HEV, 445
HIV infection, 501
PEG-IFN/RBV treatment, 370
thrombospondin-1, liver regeneration
inhibition, 6
throid, HCV infection and, 307
Tim3, CD8+ T cells, 276
tissue donation, HBV, evolved variants,
117
tissue inhibitors of metalloproteinases
(TIMPs), liver fibrosis, 10
TMC435350 (protease inhibitor),
molecule, 383
TNFR receptor-associated death domain
protein, HCV NS5A and, 232
TNF-like weak inducer of apoptosis
(TWEAK), progenitor cell
response model, 8
TNF-related apoptosis-inducing ligand
(TRAIL), HCV and, 271
tolerogenic environments, see also
immune tolerance, HCV and, 270, 277
Toll-IL-1 receptor domain containing
 adaptor-inducing interferon-β
(TRIF), HCV nonstructural
proteins and, 230
Toll-like receptors, 18–20
HBV transgenic mouse models, 177
HCV and, 270
topoisoerase 1, HBV and hepatocellular
infection, 169
“total immersion” sterilants, 564
tourists, 507
towels, decontamination with, 572
toxicity, protease inhibitors, 368–369
toxoplasmosis, 531
trafficked people, 507, 510
trans-acting elements, HBV core
promoter, 129, 133
transaminases, HAV infection, 36
transcomplementation system, HCV,
337–338
transcription, see also reverse
transcription
HBV
cccDNA, 76, 183
DNA, 75–76
RNA, 166
role of HBx, 167
transcription-mediated amplification
(TMA), 553
transfected HBV mouse models, 179–182,
183–184
transfection of cell lines, HCV, 329–331,
337
transforming growth factor beta
(TGFβ)
HCV core protein on, 356
liver regeneration inhibition, 6
transfusion-transmissible virus, 477
transgenic mouse models, HBV, 177–179,
181
immune response, 177–178, 183–184
treatments, 182–183
transhepatic arterial chemoembolization
(TACE), 544, 549
transient elastography
hemophilia, 488
HAV infection, 345, 346–347, 348, 349
recurrent hepatitis, 205
transient replication systems, HCV, 337
translation
HAV genome, 31–32
Hepadnaviridae genomes, 97
HBV genome, 76–77
transmembrane domains
evelope proteins, HCV, 226, 233
S protein, HBV, 70
transmission
HAV, 35, 43–47, 453
HBV, 82–84, 453, 455, 516, see also
perinatal transmission
blood, 516, 518, 519, 520–521
HCV, 247–252, 453.
healthcare workers, 524–526
HDV, 453
HEV, 453
variability of viruses and, 584
tree, see international travel
Tupaia belangeri, primary hepatocytes, 72–73
Trends, see regulatory T cells
TRIC-1 study, metformin, 305
triglycerides, HCV and, 224
triple therapy, chronic HCV infection, 364–368, 373
tuberculocides, 569
tuberculosis, 470
tubulins, HCV and, 225
tumor necrosis factor alpha (TNF
α), 569
T cells,
vaccines, 425–426, 428
vaccines/vaccination
hemophilia, 492
HAV, 50–58, 534
dosing schedules, 52
duration of immunity, 54
efficacy, 54–56
on epidemiology, 49
herd immunity, 56, 60
historical aspects, 30
occupational aspects, 526
safety, 53
stability of vaccine, 52
HBV, 91–94, 538
antinatal, 538
anti-HBs, response, 517, 518,
521
booster doses, 517
chronic viral hepatitis, 101,
102–105
dendritic cells, transgenic mouse
models, 182–183
duration of immunity, 92–93
epidemiological effects, 94
escape mutations, 116–117
global programs, 93–94
HBIG replacement, 211
on hepatocellular carcinoma
incidence, 164–165
HIV infection, 498
migrants, 512
non-responders, 518
occupational aspects, 517–518
protective response, 91, 92, 498, 517,
538
safety, 92
strategies, 90
tripe, 518
variants evolving, 110–112
HDV, 104
HEV capsid protein, 424, 437
HIV infection, 501
interactions, 53–54
variability of viruses, 583–584
varicella zoster virus, 536
Vaqta (hepatitis A vaccine), 50, 51
variability of viruses, 583–584
HBV, 107–126, 133–140
varicella zoster virus, 477
children, 530, 536
intrauterine liver infections, 531
vascular endothelial growth factor
receptor, liver regeneration, 6
vasculitis
HBV infection, 155–159
renal, 158
HCV infection, central nervous system,
310–311
veno-occlusive disease, 470
vertical transmission, see perinatal
transmission
very early HCC, 547
Victrrelis™, see boceprevir
vidarabin, polyarteritis nodosa, 157
Vietnam, HCV, 263
Virahep-C model, 345, 346
viral load
HBV, carriage, 557
HCV
HIV infection and, 502
treatment response, 371
HEV, pregnancy, 476–477
on T cells, 103
viremia, HAV infection, 47
virions, see also lipoviruses
HAV, 32–33, 35
HBV, 65, 69, 78–79
destruction in environment, 571
HCV, 223–224, 281, 325–326
HDV, 397–398
HEV, 419–420, 427–428
Orthohepadnavirus vs Avihepadnavirus,
97
viroids, 395
virologic breakthrough, antiviral
treatment, 198–199
virome, hepatitis A vaccines, 54
virus eradication, HCV, 364, 377, 560–561
virus-like particles (VLPs), HEV, 425, 427
vitamin D deficiency, HCV infection,
treatment response, 372
Vivaxim (hepatitis A and typhoid
c vaccine), 51
VPg (3B gene product), HAV, 30
V proteins, paramyxoviral, in vitro HCV
study, 337
VX-222 (NS5B inhibitor), 386
waterborne transmission
HAV, 46
HEV, 437
weight-based dosing, HCV infection,
560
HIV co-infection, 503
Western strains, Avihepadnavirus genus,
98
WHO International Reference Reagent
for HAV Immunoglobulin, 39
wild boars, HEV, 433
Wilson’s disease, 470
Wnt-β-catenin pathway, hepatocellular
carcinoma, 172, 356, 357
Wnt signaling, progenitor cell response
model, 7
women of reproductive age, antiviral
treatment, 192
woolly monkey, human hepatitis viruses,
582

Index 607
World Health Organization
hepatitis A vaccination, 56
hepatitis B vaccination, 93–94
wound healing, 9–10
w/r specificity, HBsAg subtypes, 109

X55 RNA, HCV, 235
XC chemokines, 17
X domain, HBV genome, 166, 168
xenotransplants, 482
chimeric mouse models, 182

X-gal, tamoxifen-inducible genetic
lineage tracing, 5
X promoter, HBV, 75, 76
X protein, see also HBx protein
Hepadnaviridae, 97

Y-box-binding protein 1, HCV, 230
yellow fever, 537
Yes-associated protein, liver
regeneration, 6
YMDD mutations, HBsAg, 119

yttrium-90 microspheres,
radioembolization, 549

ZENITH trial, 374
zidovudine, drug interactions, 491, 501
Zignego categories, extrahepatic
manifestations, HCV infection, 295–296
zinc-binding motif, NS3 protease, HCV, 229
zoonoses, 581–582
HEV, 419, 431–436, 437–438, 582